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Impact Objectives
• Produce and test a new microsystem technology for drug screening of human intracellular ion channels 
• Investigate two proteins that are involved in cancer and neurodegeneration (CLICL1 and CLIC4)
Innovations in drug screening
By bridging the fields of microfluidic engineering and biochemistry, Dr Michele Zagnoni and Dr Cheryl 
Woolhead have developed a novel and efficient method to discover and test new medications
Could you introduce the type of research 
conducted by your respective laboratories?
MZ: The Zagnoni Lab is based at the 
University of Strathclyde in Glasgow in 
the UK, in the Electronic and Electrical 
Engineering Department. Our expertise 
is in the development of microfluidic 
technologies for healthcare applications, 
including fundamental biological research, 
drug screening, personalised medicine 
therapy, organ-on-a-chip and artificial cell 
membrane constructs. As such, we bring 
to this project multidisciplinary expertise to 
create biosensors and screening platforms 
that are suitable for academic and industrial 
research.
CW: The Woolhead Lab is based at the 
University of Glasgow in the Institute of 
Molecular, Cell and Systems Biology. Our 
expertise is in the analysis of membrane 
proteins from synthesis to integration into 
the target lipid bilayer. As such, we bring 
to this project an understanding of the 
molecular properties of the proteins we are 
studying and the physiological conditions to 
optimise protein folding and integration.
You are currently developing a droplet-based 
microfluidic platform for intracellular ion 
channel drug discovery. How did you come 
to establish this project?
MZ: The Zagnoni Lab have long been 
working on microfluidic artificial cell 
membranes and we were interested in 
synthesising proteins within a droplet-
based system for facilitating drug screening 
studies. The Woolhead group has for many 
years been working on the development of 
a cell-free system for protein synthesis, to 
allow incorporation of modified aminoacyl 
tRNA molecules. Utilising a cell-free system 
such as this for high-throughput screening 
will increase the speed and lower the cost of 
such testing, allowing many more targets to 
be screened against a drug library. To achieve 
this goal an interdisciplinary approach was 
needed, which brought our two groups 
together to collaborate.
Why did you decide to focus on two proteins 
– CLIC1 and CLIC4 – specifically?
CW: The CLIC proteins are of great 
interest to us due to their reported 
involvement in various disease states, from 
neurodegenerative conditions to cancer. 
Whereas a potential inhibitor has been 
reported for CLIC1, no such inhibitors have 
been identified for CLIC4, therefore for us 
the challenge is to dissect our knowledge 
of CLIC1 and implement it into the study 
of CLIC4, underpinning the basis for new 
drug discovery approaches in the future for 
intracellular ion channels.
The project is approximately midway 
through its three-year funding period. What 
progress has been made so far? 
MZ: We have made great progress both in 
developing a robust microfluidic system 
for testing a variety of ion channels and 
in the preparation and purification of the 
CLIC proteins. Our preliminary results 
have shown our prototype is working and 
our assays have produced interesting 
mechanistic results. These will now be 
expanded on through drug testing in 
conjunction with our industrial partners.
Do you have any plans for future projects 
that you would like to share with readers?
MZ: Building on the outcomes from this 
project, we will implement the use of cell-
free expression in microfluidic systems to 
create artificial cells and explore several cell 
membrane associated processes, advancing 
our understanding of how membrane 
proteins function. In particular, we aim to 
address how viral ion channels function 
and translate the current technology for the 
study of more complex membrane proteins, 
such as GPCR channels.l
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A faster way to new medications
Researchers at the University of Strathclyde and University of Glasgow in the UK, have joined forces 
to develop an innovative method to test new drugs prior to clinical trials using synthetic biology. Their 
research has major implications for pharmaceutical drug discovery of medications targeting ion channels
Ion channels are membrane proteins, which 
generate pores that ions can pass through. 
Ion channels play an important role within 
our bodies, as they determine the physical 
processes that our tissues go through – 
from whether we will develop a pathological 
condition to simply whether our heart 
beats or nervous system operates. Since 
ion channels are frequently targeted by 
pathogens and other substances, they are of 
major research interest to those involved in 
developing pharmaceuticals. 
Drug discovery is the process by which 
new candidate medications are discovered. 
Historically, screening for drugs targeting 
ion channels has been a slow and expensive 
process. Now, however, a collaborative 
research project involving the University of 
Strathclyde and the University of Glasgow 
could provide an alternative to such 
methods, pushing the pharmaceutical 
market in a novel and more effective 
direction. 
A DIFFERENT SYSTEM
Ion channels are the second largest class 
of pharmacological drug targets, meaning 
they are key players in developing new 
medications. In conventional drug discovery, 
an automated patch-clamp method is used 
to study the electrophysiological currents 
through ion channels and therefore identify 
drugs of interest. However, this method 
cannot be used to study intracellular ion 
channels, meaning a whole slew of therapeutic 
potential cannot be adequately investigated. 
Dr Michele Zagnoni of the University of 
Strathclyde and Dr Cheryl Woolhead of the 
University of Glasgow have come together 
to produce and test a new microsystem 
technology aimed at screening drugs 
using intracellular ion channels. They are 
working to develop microfluidic artificial 
cell membranes and a cell-free system of 
protein synthesis. Their goal is to increase 
the speed and lower the cost of drug 
screening. ‘Microfluidics offers the ability 
to create synthetic cells that can be used 
for drug screening, avoiding higher costs 
and challenges implicated with live cell 
measurements,’ elaborates Zagnoni. 
By means of these microfluidic technologies 
and cell-free protein synthesis, their 
research offers a controlled way to create in 
vitro models of biological systems. By using 
these models, they can use intracellular ion 
channels to identify, discover and develop 
new chemical compounds for medications. 
Because these procedures take place before 
clinical trials, their increased efficiency 
identifying drugs is expected to improve 
outcomes of the clinical trials that follow. 
INNOVATIVE COLLABORATION
The Zagnoni Lab is focused on 
bioengineering, while the Woolhead Lab 
is focused in molecular biochemistry. ‘The 
work carried out in the two laboratories is 
very different,’ explains Woolhead. ‘As such, 
this partnership allows us to think about the 
problem much more laterally, from analysing 
the most efficient way to create our tests,  
to the most physiological way and finding  
a constructive path through the middle.’ 
Both laboratories are located in Glasgow 
and their proximity to one another has 
enabled the labs to develop a close 
relationship alongside a state-of-the-art 
approach to drug discovery. The Zagnoni 
Lab focuses on microfluidic technology, 
screening compounds on human tissue and 
assessing characteristics of cellular function 
in microfluidic environments. At the same 
time, the Woolhead Lab performs in-depth 
analysis of membrane proteins, from their 
synthesis to their integration into the 
lipid bilayer. Woolhead has also published 
research on the early stages of protein 
folding and is currently studying structural 
changes in proteins during lipid integration. 
The novelty of Zagnoni and Woolhead’s 
work is certainly in their collaboration. By 
combining biochemistry and microfluidic 
engineering, they have been able to make 
novel advances in synthetic biology. 
MOVING FORWARD
So far, Zagnoni and Woolhead are on 
track to reach their goal of establishing a 
microfluidic platform for intracellular ion 
channel drug discovery. The next step is to 
implement their microfluidic system into a 
semi-automatic prototype suitable for drug 
screening using artificial cell membranes.
At present, they are investigating CLIC1 
and CLIC4, two proteins implicated in a 
range of pathological conditions. While 
there is a known inhibitor for CLIC1, this 
is not the case for CLIC4. Future research 
will aim to identify a compound that would 
modulate the activity of CLIC4 ion channels. 
Such a discovery would be the first of its 
kind. Additionally, Zagnoni and Woolhead 
are working with two industrial partners, 
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BIOGRAPHIES
Dr Michele Zagnoni is a Senior Lecturer 
and Group Leader of the Microfluidic 
Group in the Electronic and Electrical 
Engineering Department at the 
University of Strathclyde, Glasgow. 
He has extensive expertise in bridging 
microfluidic technology to biological 
applications in the areas of cancer 
research, neuroscience and ion 
channel characterisation. Recently, he 
became the Chief Scientific Officer of 
ScreenIn3D, a joint venture company 
that provides drug screening services 
based on microfluidics and 3D cell 
culture.
 
Dr Cheryl Woolhead is the Deputy 
Director of the Institute of Molecular, 
Cell and Systems Biology in the College 
of Medical, Veterinary and Life Sciences 
at the University of Glasgow. She has 
worked on membrane proteins and their 
structures for over 20 years, focusing on 
the early folding of proteins within the 
ribosome tunnel and investigating how 
ribosome/nascent chain interactions 
affect translation and cellular targeting.
Apconix and Smartox. Their partnership 
with pharmaceutical companies will allow 
them to test their method using current 
pharmaceutical drug screening scenarios, as 
well as test their system with animal-derived 
molecules, which could lead to novel drug 
identification. 
MULTI-LAYERED EFFECTS
Zagnoni and Woolhead’s research is 
expected to have positive consequences 
across not only industrial, but also 
academic, economic and societal 
realms. From an academic standpoint, 
their research is seeking to enhance 
understanding of membrane proteins, 
specifically the mechanisms of intracellular 
membrane protein structures. They are 
also looking into the functional role of 
controllable artificial cell membranes. These 
studies could open up a plethora of research 
opportunities. Zagnoni and Woolhead are 
already working hard to disseminate their 
project outputs and develop relationships 
with labs around Europe, and so maximise 
their research impact. 
Economically, this new system of drug 
screening would allow a decrease in 
developmental expenditure of certain 
pharmaceuticals. This would make clinical 
trials more affordable, allowing new and 
necessary medications to be available more 
quickly. The preclinical phase, where new 
compounds are discovered and identified, 
accounts for a third of the total cost of 
clinical trials. By making savings at this 
stage, total clinical trial expenditure is likely 
to be significantly reduced. 
Most importantly, by developing an 
inventive and efficient way to perform 
drug testing, there will be considerable 
societal implications. Because these initial 
screenings will lead to new economic and 
effective medications, patients should have 
greater access to vital interventions. This 
means reduced mortality and morbidity and 
improved quality of life for patients. 
By merging fields, Zagnoni and Woolhead 
have made leaps and bounds toward 
developing a microfluidic platform for 
intracellular ion channel drug discovery. 
Their innovative use of synthetic biology is 
likely to facilitate drug testing at a higher 
throughput – paving the way for more 
thorough, fast and effective processing 
of new medications and pharmaceutical 
innovations than ever before. l
Microfluidics offers the ability to create synthetic 
cells that can be used for drug screening, avoiding 
higher costs and challenges implicated with live 
cell measurements
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